Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Por Leonardi, Craig, Reich, Kristian, Foley, Peter, Torii, Hideshi, Gerdes, Sascha, Guenther, Lyn, Gooderham, Melinda, Ferris, Laura K., Griffiths, Christopher E. M., ElMaraghy, Hany, Crane, Heidi, Patel, Himanshu, Burge, Russel, Gallo, Gaia, Shrom, David, Leung, Ann, Lin, Chen-Yen, Papp, Kim
Publicado no Dermatol Ther (Heidelb) (2020)